With this background, we aimed to evaluate the possible protective role of perinatal treatment with leptin and celastrol, the latter of which has been described as a leptin sensitizer with anti-obesity properties [13], and their combination, against metabolic alterations related to the diet-induced MOWN phenotype. The gene discussed is LEP; the disease is obesity disorder.